Compare Oxford Lane Capital Corp (OXLC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oxford Lane Capital Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Oxford Lane Capital Corp trades at $9.67 (market cap $942.56M), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 88.5× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (24.96%). Which is the better fit depends on your goals.
| OXLC | REGN | |
|---|---|---|
Market Cap | $942.56M | $83.43B |
Sector | Financials | Health |
52-Week High | $17.73 | $852.03 |
52-Week Low | $8.15 | $555.51 |
Dividend Yield | 24.96% | 0.46% |
Enterprise Value | — | $78.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $9.61, down 0.52% on the day, with a bullish technical signal supported by moving averages but mixed earnings performance. Recent quarters show significant misses versus expectations, including a large loss in Q1 2026, though the company maintains a steady dividend payout. Net income margin is exceptionally high at 100.85% for 2026, but this follows negative revenue, while 2025 showed positive net income of $48.46M. The P/B ratio of 0.91 suggests the stock trades below book value.
Outlook is cautious due to volatile earnings and high yield sustainability concerns, with analyst sentiment split evenly between buy and sell ratings. Key risks include earnings instability and reliance on financing cash flow, but the discount to book value and consistent dividends may appeal to income-focused investors amid bullish technical trends.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
